DECLINE IN PNEUMOCOCCAL DISEASE IN YOUNG CHILDREN, AND DECLINE IN PNEUMOCOCCAL CARRIAGE IN ALL AGES, FOLLOWING PCV10 INTRODUCTION IN FIJI

Author(s):  
Kim Mulholland
PLoS ONE ◽  
2013 ◽  
Vol 8 (10) ◽  
pp. e76309 ◽  
Author(s):  
Romina Camilli ◽  
Laura Daprai ◽  
Francesca Cavrini ◽  
Donatella Lombardo ◽  
Fabio D’Ambrosio ◽  
...  

2006 ◽  
Vol 55 (8) ◽  
pp. 975-980 ◽  
Author(s):  
Stuart C. Clarke

In 2000, a multi-valent pneumococcal conjugate vaccine, known as Prevnar, was licensed for use in infants and young children in the USA. The subsequent introduction of the vaccine into the childhood immunization schedule in that country led to a significant decrease in pneumococcal disease. The vaccine is effective against invasive and non-invasive pneumococcal infection, can be used in young children as well as adults and, like all conjugate vaccines, provides long-lasting immunity. Moreover, it reduces the incidence of antibiotic resistance because a number of resistant serotypes are targeted by the vaccine. Prevnar, also known as Prevenar, has since been licensed in numerous countries, including the UK. On 8 February 2006, the Departments of Health in England, Scotland and Wales announced the inclusion of Prevenar in the childhood immunization schedule. This announcement has important implications for pneumococcal infection, disease surveillance and immunization policy in the UK.


2009 ◽  
Vol 48 (s2) ◽  
pp. S114-S122 ◽  
Author(s):  
Eleri J. Williams ◽  
Stephen Thorson ◽  
Mitu Maskey ◽  
Sandeep Mahat ◽  
Mainga Hamaluba ◽  
...  

2002 ◽  
Vol 9 (5) ◽  
pp. 1032-1038 ◽  
Author(s):  
Anu Soininen ◽  
Maijastiina Karpala ◽  
Sirkka-Liisa Wahlman ◽  
Hannele Lehtonen ◽  
Helena Käyhty

ABSTRACT An enzyme immunoassay (EIA) for antibodies to pneumococcal capsular polysaccharides (Pnc PSs) detects in some cases antibodies that are cross-reactive within different Pnc PSs. Recently, it has been suggested that for detection of only serotype-specific antibodies, EIA can be modified by removing cross-reactive antibodies by absorption with an irrelevant PS, e.g., the type 22F PS. The opsonophagocytosis assay measures the functional activities of antibodies in vitro, and the results of that assay correlate with in vivo protection better than measurement of the antibody concentration by EIA. We compared these different methods for measuring antibodies to type 1, 6B, 11A, 14, 19F, and 23F Pnc PSs in the sera of unimmunized young children who had been monitored for pneumococcal carriage, acute otitis media, and acquisition of antibodies to Pnc PSs from 2 to 24 months of age. Serum samples with antibody increases after contact with a pneumococcus of a homologous serotype contained specific antibodies and often had opsonophagocytic activity (OPA) (20 of 46). In samples with antibody increases from children who had not had contact with a pneumococcus of a homologous serotype, the antibodies found to be type specific by conventional EIA were usually cross-reactive and infrequently had OPA (10 of 68). When type 22F PS absorption was used in the EIA, most of the false antibody increases were eliminated, but most of the true antibody increases were still detected and the association between the antibody concentration detected by EIA and OPA was improved. However, there were serotype-dependent differences in the frequency of OPA. Use of absorption with a heterologous PS in EIA should be encouraged, and both the specificity of EIA and the sensitivity of opsonophagocytic assays should be further evaluated and improved.


2021 ◽  
Vol 50 (Supplement_1) ◽  
Author(s):  
Eleanor Neal ◽  
Jocelyn Chan ◽  
Fiona M. Russell ◽  
Cattram. D Nguyen

Abstract Background Pneumococcal disease is a major contributor to global childhood morbidity and mortality. Pneumococcal carriage is a prerequisite for pneumococcal disease. Identifying factors associated with pneumococcal carriage can aid public health intervention programs. It is unknown if risk factors for pneumococcal carriage differ between low, middle, and high-income countries. We present preliminary findings of our systematic review of factors associated with pneumococcal carriage in community settings, in all ages. Methods A systematic search for pneumococcal nasopharyngeal carriage studies, published in English before July 2019. Two researchers independently reviewed studies that described factors associated with pneumococcal nasopharyngeal carriage. Study quality was assessed using the NIH Study Quality Assessment Tools. Results are presented as narrative summaries due to heterogeneity amongst factor definitions. Results Preliminary results are shown. Sixty-seven studies were included. 49% were conducted in high-income countries. Pneumococcal prevalence ranged from 0.3%-97%, 2.6%-89.6%, 14%-73%, 1.6%-82.4% in low-, lower-middle, upper-middle, and high-income classifications. Age, respiratory tract infection symptoms, living with young children, poverty, exposure to smoke, and season were positively associated with pneumococcal carriage in all income classifications. Conclusions Pneumococcal carriage prevalence was highest in low-income classifications. Pneumococcal carriage is associated with similar factors across income classifications. Differences in prevalence of risk factors associated with pneumococcal carriage by income classification may contribute to differences in carriage prevalence by income classifications. Key messages Pneumococcal carriage is considered a prerequisite for pneumococcal disease. Pneumococcal carriage prevalence is highest in low-income countries, however preliminary results suggest risk factors for carriage may be similar across income classifications.


Author(s):  
A Anglemyer ◽  
A McNeill ◽  
K DuBray ◽  
G J B Sonder ◽  
T Walls

Abstract New Zealand (NZ) became one of few countries to shift from PCV13 to PCV10 in 2017. The number of serotype 19A cases in young children and the proportion of isolates that are penicillin-resistant have been steadily increasing since. It is time for NZ to reconsider its choice of pneumococcal vaccine.


2001 ◽  
Vol 16 (3) ◽  
pp. 42-44
Author(s):  
Diana Steimle ◽  
Robert Aston ◽  
Pierre Van Damme

Sign in / Sign up

Export Citation Format

Share Document